Mocertatug rezetecan (HS-20089, GSK5733584) is an antibody-drug conjugate (ADC) targeting B7-H4. Mocertatug rezetecan exhibits activity against platinum-resistant ovarian cancer. Mocertatug rezetecan is used for the research of advanced solid tumors, especially ovarian cancer and triple-negative breast cancer[1][2].
Purity:
97.29
CAS Number:
[3042848-25-6]
Target:
Antibody-Drug Conjugates (ADCs)
Application Notes:
MCE Product type: ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted